DNTH
Dianthus Therapeutics, Inc. /DE/
Key Financials
Net Income
$-162337000
↓ 91.1%
Operating Income
$-177933000
↓ 74.7%
Revenue
$2.0M
↓ 67.3%
Total Liabilities
$37.5M
↑ 74.3%
EPS (Diluted)
$-4.20
↓ 64.7%
Total Assets
$530.9M
↑ 42.0%
Shareholders' Equity
$493.4M
↑ 40.0%
Cash & Equivalents
$51.1M
↑ 124.1%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 8/14/2026 | View on SEC |
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| SCHEDULE 13G | 8/13/2026 | View on SEC |
| 4 | 8/11/2026 | View on SEC |
| 4 | 8/11/2026 | View on SEC |
| 4 | 8/11/2026 | View on SEC |
| 144 | 8/10/2026 | View on SEC |
| 144 | 8/10/2026 | View on SEC |
| 144 | 8/10/2026 | View on SEC |
| 4 | 8/7/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | DNTH |
| Company Name | Dianthus Therapeutics, Inc. /DE/ |
| CIK | 1690585 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 929-999-4055 |